SECsense Logo

Benitec Biopharma Inc. 8-K Report: Key Insights from February 14, 2025 Filing

$BNTC
Form 8-K
Filed on: 2025-02-14
Source
Benitec Biopharma Inc. 8-K Report: Key Insights from February 14, 2025 Filing

Based on the provided section of a financial report, here are the key insights and information extracted:

  1. Entity Identification:
  • Company Name: Benitec Biopharma Inc.
  • CIK Number: 0001808898
  • Stock Exchange: NASDAQ
  • Ticker Symbol: BNTC
  • Entity Type: Delaware Corporation (indicated by "DE")
  1. Contact Information:
  • Address: 3940 Trust Way, Hayward, CA 94545
  • Phone Number: (510) 780-0819
  1. Filing Details:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: February 14, 2025
  • Period Covered: The report pertains to a single day, February 14, 2025.
  1. Common Stock Information:
  • Par Value: $0.0001
  1. Regulatory References:
  • The report is structured in XBRL (eXtensible Business Reporting Language) format, which is used for financial reporting to the SEC.

Insights:

  • The filing is an 8-K, indicating that Benitec Biopharma Inc. may have experienced a significant event or change that requires immediate disclosure. Stakeholders should look for more detailed content in the 8-K report to understand the nature of the event.
  • The single-day reporting period suggests that the information disclosed might be time-sensitive and could impact market perception or stock performance.
  • The low par value of the common stock ($0.0001) may indicate a high number of shares outstanding or a low stock price, which could be relevant for investors assessing the company's market capitalization and share structure.

Investors and analysts should review the complete 8-K filing for a deeper understanding of the events leading to this filing and any potential implications for the company’s operations or financial standing.